Genomically matched therapy in refractory colorectal cancer according to ESMO Scale for Clinical Actionability of Molecular Targets: experience of a comprehensive cancer centre network

Efficiency of expanded genomic profiling (EGP) programmes in terms of final inclusion of patients in genomically matched therapies is still unknown. Fit patients with advanced and refractory colorectal cancer (CRC) were selected for an EGP programme. Next‐generation sequencing (NGS) analysis from fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Mulet Margalef, Núria, Castillo, Carmen, Mosteiro, Miguel, Pérez, Xavier, Aguilar, Susana, Ruíz‐Pace, Fiorella, Gil, Marta, Cuadra, Carmen, Ruffinelli, José Carlos, Martínez, Mercedes, Losa, Ferran, Soler, Gema, Teulé, Àlex, Castany, Roser, Gallego, Rosa, Ruíz, Andrea, Garralda, Elena, Élez, Elena, Vivancos, Ana, Tabernero, Josep, Salazar, Ramon, Dienstmann, Rodrigo, Santos Vivas, Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483603/
https://www.ncbi.nlm.nih.gov/pubmed/37097008
http://dx.doi.org/10.1002/1878-0261.13444

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483603/
https://www.ncbi.nlm.nih.gov/pubmed/37097008
http://dx.doi.org/10.1002/1878-0261.13444

Ejemplares similares